Floatz logo

Rintatolimod

Colorectal Tumors

Roswell Park Cancer InstitutePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Colorectal Tumors cohort.

Asset / SponsorPhaseRating
Ad-Cea Vaccine
National Cancer Institute (NCI)
Phase 2CCC
Everolimus
The Queen Elizabeth Hospital
Phase 1/2CCC
Nelfinavir
Maastricht Radiation Oncology
Phase 1/2CCC
Avelumab
National Cancer Institute (NCI)
Phase 2CCC
INTERFERON ALFA-2B
Roswell Park Cancer Institute
Phase 1/2CCC

Same molecule, other indications

Rintatolimod is also rated in:

breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
estrogen-receptor negative breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →